Abstract
Edible mushroom based compounds are novel source of anti-cancer compounds. Present investigation aims to study the molecular interaction of potential mushroom derived compounds for their anti-cancer activity. The current work reports twenty two potential mushroom compounds based on the Molecular Docking results with binding site of mouse double minute 2 (Mdm2) homolog receptor model, over expression of which inhibits the activity of p53 in most of the cancer cases. Compounds namely, hispidin (−82.625), lucidenic acid (−76.205) and cordycepin (−74.825) has been identified as novel inhibitors of Mdm2 receptor in terms of least docking scores and hydrogen bonding interaction with reference to chromenotriazolopyridine. Absorption, distribution, metabolism, excretion and toxicity results of these three compounds were found positive and optimal. Therefore, predicted mushroom derived compounds in the present study may be promising starting points for designing Mdm2 inhibitors as future therapeutics of cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
